Malaria Vaccines Market Future Scope Shows Huge growth over the forecast period
Malaria Vaccine According to World Health Organization statistics, about half of the world's population is at risk of malaria (WHO). As a result, numerous healthcare organisations have been more interested in solving this serious problem. The Melinda Gates Foundation and PATH, two global non-profit organisations, are trying to develop malaria prevention techniques and save the lives of many people in malaria-affected areas. Because Africa accounts for 90% of malaria occurrences, the introduction of GlaxoSmithKline plc's first malaria vaccine is aimed primarily at this continent. Mosquirix was approved by the European Union in 2015 and is currently being tested in Africa as part of a pilot project. The global Malaria Vaccines Market is expected to be valued at US$ 50.6 million in 2024 and is expected to witness a CAGR of 150.0% during the forecast period (2024 – 2027). This mosquito-borne infection causes severe illness in both children and adults. The effects of high fever